Endocrine and Diabetes Biomarkers

A biomarker is any substance, structure, or process that should be measurable in the body or its products and it also influences or predicts the incidence of outcome or disease. For predicting type 1 diabetes, a biomarker should be present in a subset of the population, and this subset should have an influence on the proportion of people in whom this type 1 diabetes develops. A biomarker should also present a significant risk for the development of type 1 diabetes within a defined period of time or diagnose a “stage” in the progression to clinical or symptomatic type1 diabetes. As described in this article, most of the biomarkers are  used for the prediction of type 1 diabetes are islet-specific supporting the concept that, before overt hyperglycaemia, type 1 diabetes is generally predominantly a targeted disease rather than a systemic disease.

Atomic Biomarkers can be separated as a trademark that is precisely measured and gaged as a pointer of typical natural methods, pathogenic methodology, or pharmacologic reactions to a pharmaceutical intercession.

Biomarkers have fundamental influences in driving clinical trials and treating the patients. Progress in sub-atomic diagnostics helps medicinal experts make proficient, experimentally legitimate choices. All the more efficient disclosure and use of biomarkers in the development of ant diabetes medications will rely on upon quickening our comprehension of the pathogenesis of diabetes and particularly its macro vascular entanglements. Procedural upgrades in different fields, particularly tumour, are started to demonstrate the way towards the better models of diabetes pathogenesis and atomic biomarker revelation.

 

  • Prognostic marker
  • Diabetic nephropathy marker
  • Molecular marker for metabolic syndrome
  • Molecular Marker-Hypoglycaemic response
  • Inflammatory markers: Type 2 diabetes

Related Conference of Endocrine and Diabetes Biomarkers

August 23-24, 2021

30th European Diabetes Congress

Vienna, Austria
September 02-03, 2021

5th Annual Congress on Diabetes, Obesity and Its Complications

Vienna, Australia
September 06-07, 2021

30th World Diabetes & Heart Congress

, Singapore
September 08-09, 2021

17th World Congress on Endocrinology & Diabetes

Prague, Czech Republic
September 20-21, 2021

15th European Diabetes and Endocrinology Congress

London, UK
September 23-24, 2021

20th International Conference on Obesity

Paris, France
October 14-15, 2021

Global congress on Endocrinology and Gynecology

Sydney, Australia
October 25-26, 2021

2nd Annual Summit on Diabetes and Endocrinology

Rome, Italy
October 25-26, 2021

23rd World Congress on Diabetes and Endocrine Disorders

Toronto, Canada
October 28-29, 2021

2nd Global summit on Diabetes and Endocrinology

Amsterdam, Netherlands
October 28-29, 2021

3rd Annual Conference on Diabetes and Endocrinology

Zurich, Switzerland
November 09-10, 2021

International Congress and Expo on Diabetic Care

Bangkok, Thailand
November 15-16, 2021

International Conference on Diabetes & Heart Diseases

Auckland, Newzealand
November 16-17, 2021

World congress and Expo on Diabetes

Osaka, Japan
November 29-30, 2021

World Summit on Blood Glucose Monitoring

Vancouver, Canada
December 07-08, 2021

13th World Congress on Endocrinology and Metabolic Disorders

Auckland, Newzealand
February 21-22, 2022

2nd World Summit on Diabetes

Prague, Czech Republic
May 27-28, 2022

International Endocrinology Congress

Rome, Italy

Endocrine and Diabetes Biomarkers Conference Speakers

Recommended Sessions

Related Journals

Are you interested in